Dose-by-dose weight loss in Phase 2 (NEJM) Phase 2 NEJM weight loss by dose, 24 and 48 weeks Dose 1 mg 24 weeks -7.2% 48 weeks -8.7% Dose 4 mg 24 weeks -12.9% 48 weeks -17.5% Dose 8 mg 24 weeks -15.7% 48 weeks -22.8% Dose 12 mg 24 weeks -17.5% 48 weeks -24.2% Dose Placebo 24 weeks -1.6% 48 weeks -2.1% Source: Jastreboff et al., NEJM 2023
International journal of obesity (2005), 10.1038/s41366-024-01500-y
In the last 20 years, the emergence of pharmacological treatments for obesity based on gastrointestinal hormones has transformed the therapeutic landscape
The B12 causes the color, not a problem with the semaglutide itself
Stopping Lexapro abruptly can lead to withdrawal symptoms, and stopping Semaglutide may result in a return of high blood sugar levels or weight gain
Disclaimer: Always refer to the official ColonBroom website for full ingredient information, clinical data references, and the latest satisfaction guarantee terms